Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.
复制标题
DOI:
10.1021/mp900245h
复制
发表时间:
2010-02-01
影响因子:
4.9
通讯作者:
Chakrapani H
中科院分区:
文献类型:
--
作者:
Kumar V;Hong SY;Maciag AE;Saavedra JE;Adamson DH;Prud'homme RK;Keefer LK;Chakrapani H
Here we report the stabilization of the nitric oxide (NO) prodrugs and anti-cancer lead compounds, PABA/NO (O2-{2,4-dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl} 1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate) and “Double JS-K” (1,5-bis{[1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diol-2-ato]-2,4-dinitrobenzene), through their incorporation into polymer-protected nanoparticles. The prodrugs were formulated in block copolymer-stabilized nanoparticles with sizes from 220 to 450 nm by a novel rapid precipitation process. The block copolymers, with polyethylene glycol (PEG) soluble blocks, provide a steric barrier against NO prodrug activation by glutathione. Too rapid activation and NO release has been a major barrier to effective administration of this class of compounds. The nanoparticle stabilized PABA/NO from attack by glutathione as evidenced by a significant increase in time taken for 50% decomposition from 15 min (unformulated) to 5 h (formulated); in the case of Double JS-K, the 50% decomposition time was extended from 4.5 min (unformulated) to 40 min (formulated). The more hydrophobic PABA/NO produced more stable nanoparticles and correspondingly more extended release times in comparison with Double JS-K. The hydrophobic blocks of the polymer were either polystyrene or polylactide. Both blocks produced nanoparticles of approximately the same size and release kinetics. This combination of PEG-protected nanoparticles with sizes appropriate for cancer targeting by enhanced permeation and retention (EPR) and delayed release of NO may afford enhanced therapeutic benefit.
登录
查看更多内容
影响因子:
11.2
作者:
Findlay, Victoria J.;Townsend, Danyelle M.;Tew, Kenneth D.
通讯作者:
Tew, Kenneth D.
影响因子:
4.7
作者:
Liu, Ying;Cheng, Chungyin;Fox, Rodney O.
通讯作者:
Fox, Rodney O.
影响因子:
19
作者:
Akbulut, Mustafa;Ginart, Paul;Prud'homme, Robert K.
通讯作者:
Prud'homme, Robert K.
影响因子:
3.7
作者:
Johnson, BK;Prud'homme, RK
通讯作者:
Prud'homme, RK
影响因子:
2.7
作者:
Chakrapani, Harinath;Goodblatt, Michael M.;Saavedra, Joseph E.
通讯作者:
Saavedra, Joseph E.